Short Interest in Evogene Ltd. (NASDAQ:EVGN) Decreases By 77.2%

Evogene Ltd. (NASDAQ:EVGN) saw a large drop in short interest in the month of August. As of August 31st, there was short interest totaling 53,001 shares, a drop of 77.2% from the August 15th total of 232,078 shares. Currently, 0.7% of the company’s shares are sold short. Based on an average daily volume of 219,870 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Evogene in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Evogene Trading Down 0.1%

Shares of EVGN traded down $0.00 during mid-day trading on Friday, hitting $0.48. The company’s stock had a trading volume of 2,453,974 shares, compared to its average volume of 164,677. The company’s 50-day moving average is $0.55 and its 200-day moving average is $0.66. Evogene has a 52-week low of $0.37 and a 52-week high of $1.50. The firm has a market capitalization of $4.19 million, a price-to-earnings ratio of -0.53 and a beta of 1.41.

Insiders Place Their Bets

In other news, Director Leon Recanati bought 460,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was acquired at an average cost of $0.64 per share, with a total value of $294,400.00. Following the transaction, the director directly owned 1,343,886 shares in the company, valued at approximately $860,087.04. This trade represents a 52.04% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.40% of the stock is currently owned by company insiders.

Institutional Trading of Evogene

Several hedge funds and other institutional investors have recently bought and sold shares of EVGN. Citadel Advisors LLC raised its position in shares of Evogene by 169.4% in the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 36,206 shares in the last quarter. XTX Topco Ltd bought a new stake in Evogene during the fourth quarter valued at about $25,000. Finally, Jane Street Group LLC boosted its position in Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,387 shares in the last quarter. Institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.